Dove Hair highlights new formulas during Dove Great Hair Affair Tour
ENGLEWOOD CLIFFS, N.J. — Unilever’s Dove Hair is introducing the new Dove Daily Moisture and Dove Intensive Repair formulas at the Dove Great Hair Affair Tour presented by Glamour.
The new Dove Daily Moisture promises to deliver up to five times smoother hair in just one wash, and Dove Intensive Repair is designed to provide smoothness and makes hair stronger by reducing breakage and preventing split ends.
Women can check out the new formulas by stopping by the Dove Great Hair Affair. The tour features a free wash and style — on a first come, first serve basis — with the new Dove Daily Moisture formulas, as well as free samples. The tour is coming to New York City, Chicago and Los Angeles between now and July 25.
Mylan looks to become first to market generic ulcerative proctitis drug
PITTSBURGH — Mylan is challenging a patent on a drug used to treat ulcerative proctitis, the generic drug maker said Thursday.
Mylan said it had filed a regulatory approval application with the Food and Drug Administration for melamine rectal suppositories in the 1,000-mg strength. The drug is a generic version of Canasa, which had sales of about $153 million during the 12-month period that ended in March, according to IMS Health.
Mylan’s application contained a Paragraph IV certification, a legal assertion that patents covering the drug are invalid, unenforceable or not in danger of infringement. In response to the filing, Aptalis, the company that makes Canasa, filed a patent-infringement suit against Mylan in the U.S. District Court for the District of New Jersey.
Under regulations governing generic drugs, Mylan expects to be eligible for 180 days of market exclusivity after the FDA approves the drug.
FDA approves Kremers Urban generic ADHD drug
PRINCETON, N.J. — The Food and Drug Administration has approved a Kremers Urban Pharmaceuticals drug for treating attention deficit hyperactivity disorder, the UCB subsidiary said.
KU announced the approval of methylphenidate hydrochloride extended-release tablets in the 18-mg and 27-mg strengths.
The drug is a generic version of Johnson & Johnson’s Concerta QD.
The company also received tentative approval from the FDA for the 36-mg and 54-mg strengths of the drug and will be allowed to receive final approval after the expiration of the exclusivity period for the drug in September 2013.